NYSE:MRKPharmaceuticals
Does New KEYTRUDA EU Ovarian Cancer Approval Reshape The Bull Case For Merck (MRK)?
Earlier this month, Merck announced positive Phase 3 data for its investigational oral PCSK9 inhibitor enlicitide and secured European Union approval for KEYTRUDA in combination with paclitaxel, with or without bevacizumab, for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express PD-L1.
These developments extend Merck’s reach in both cardiovascular and oncology care, potentially diversifying its product mix as it prepares for...